AMH + FSH Test at Home (Anti-Müllerian Hormone & Follicle-Stimulating Hormone)

The AMH + FSH combination blood test is one of the most important panels for evaluating ovarian reserve and reproductive health in women. It brings together two complementary hormone markers that, when read side by side, reveal far more about fertility potential than either test used alone.

AMH reflects the size of the remaining egg pool in the ovaries. FSH reflects how hard the pituitary gland is working to drive follicle development each cycle. Together, they create a dual-lens view of where a woman stands in her reproductive timeline.

MAX@Home makes this test available at your doorstep. A certified phlebotomist visits at your preferred time, collects the sample with sterile equipment, and your digitally authenticated report is delivered within 24 to 48 hours.

What Anti-Müllerian Hormone (AMH) Measures

AMH is produced by the granulosa cells surrounding the small antral follicles in the ovaries. The amount of AMH circulating in the blood is a direct reflection of how many follicles remain, giving clinicians a reliable snapshot of ovarian reserve.

What makes AMH particularly valuable as a clinical tool is that it does not fluctuate across the menstrual cycle. It can be measured on any day of the month and will give a consistent reading, unlike many other reproductive hormones that rise and fall with the cycle.

Key facts about AMH

• AMH declines steadily with age, peaking in the mid-twenties and becoming undetectable after menopause.
• Low AMH indicates a smaller-than-expected egg pool for a woman's age.
• Very high AMH is commonly associated with polycystic ovary syndrome (PCOS) due to excess follicle numbers.
• AMH is used to predict ovarian response before IVF stimulation, helping to dose gonadotrophin injections accurately.
• AMH can decline rapidly after chemotherapy, radiation, or ovarian surgery, making it a useful monitoring marker after these treatments.

Age-related AMH decline

AMH levels follow a predictable downward trajectory as women age. From peak levels in the early twenties, AMH declines gradually through the thirties and then more steeply in the forties. A woman's AMH at age 35 is typically half or less of what it was at 25. Understanding this trajectory helps clinicians interpret whether a woman's AMH is appropriate for her age or significantly below the expected range, which is where clinical concern begins.

Age-adjusted AMH interpretation is important because a reading of 1.5 ng/mL may be acceptable for a 38-year-old but concerning for a 29-year-old. Fertility specialists always interpret AMH within the context of the patient's age and symptom picture.

What Follicle-Stimulating Hormone (FSH) Measures

FSH is released by the pituitary gland and signals the ovaries to develop follicles during the first half of the menstrual cycle. In a woman with a healthy egg supply, the ovaries respond readily, and FSH levels remain low. As the ovarian reserve declines, the ovaries become less responsive, and the pituitary compensates by releasing more FSH in an attempt to stimulate what remains.

FSH is most informative when measured on Day 2 or Day 3 of the menstrual cycle, when it reflects the baseline hormonal state before any follicle has been selected for that cycle. A rising FSH on this baseline measurement is one of the earliest hormonal signs of declining ovarian function.

Key facts about FSH

• FSH below 10 mIU/mL on Day 2/3 indicates normal ovarian reserve.
• FSH between 10 and 15 mIU/mL is borderline elevated and warrants monitoring.
• FSH above 15 mIU/mL suggests reduced ovarian reserve.
• FSH above 25 mIU/mL is associated with perimenopause or premature ovarian insufficiency.
• FSH can fluctuate from cycle to cycle, so a single elevated reading may need to be repeated before conclusions are drawn.

Why FSH timing matters

FSH is not a static hormone. It rises during the second half of the follicular phase as a selected follicle grows, and it surges mid-cycle to trigger ovulation. Measuring FSH on any day other than Day 2 or Day 3 produces a result that does not reflect the baseline reserve status and may be misleading. Day 2 or Day 3 is the window when FSH should be at its lowest if the ovaries are functioning normally. Elevated FSH on these days means the pituitary is already compensating for diminished ovarian responsiveness at the start of the cycle.

Why Test AMH and FSH Together

Testing both markers in a single panel gives a much more complete and reliable picture than relying on one value alone.

• A low AMH combined with an elevated FSH provides convergent evidence of diminished ovarian reserve from two independent pathways.
• A high AMH with a normal or low FSH, particularly in women with irregular cycles, is a characteristic hormonal signature of PCOS.
• When AMH and FSH give discordant readings, such as a borderline AMH with a still-normal FSH, it may indicate an early transitional phase that warrants closer monitoring.
• Because AMH is stable across the cycle while FSH needs to be timed to Day 2 or 3, combining them in one home visit maximises the clinical information obtained from a single blood draw.
• For IVF planning, both markers together refine stimulation protocol decisions and help predict both poor-response and hyper-response risks.

Concordant and discordant results

When AMH and FSH point in the same direction, the clinical picture is clear. Low AMH and high FSH together confirm diminished reserve through two separate biological pathways, giving the specialist confidence to act. High AMH and low FSH together confirm a large follicle pool, which in the right clinical setting is consistent with PCOS.

Discordant results, where one marker appears normal and the other does not, are more challenging to interpret. A patient with a low-normal AMH but a still-normal FSH may be in an early transitional phase where the egg pool is already declining but the pituitary has not yet begun to compensate. This pattern warrants repeat testing in three to six months rather than a definitive conclusion from a single measurement.

Conditions and Clinical Scenarios This Test Evaluates

Diminished Ovarian Reserve

Low AMH and elevated FSH together are the hallmark biochemical pattern of diminished ovarian reserve (DOR). DOR can occur due to natural ageing, genetic conditions such as Turner syndrome or premutation of the FMR1 gene, autoimmune ovarian damage, pelvic infections, endometriosis, or prior treatment with chemotherapy or radiation.

Identifying DOR early is critical because it informs decisions about the timing of natural conception attempts, the urgency of fertility treatment, and the need for egg freezing while reserves are still present.

Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) is defined as loss of normal ovarian function before the age of 40. In POI, AMH is typically very low or undetectable, while FSH is significantly elevated, often exceeding 25 mIU/mL on two readings taken more than four weeks apart. Early diagnosis matters because POI carries implications beyond fertility, including oestrogen deficiency effects on bone density and cardiovascular health.

Polycystic Ovary Syndrome (PCOS)

PCOS is characterised by an excess number of small antral follicles, which drives AMH to abnormally high levels. The AMH + FSH panel helps confirm the hormonal picture of PCOS and distinguish it from other causes of irregular periods. Very high AMH in a woman planning IVF also signals a risk of ovarian hyperstimulation syndrome (OHSS), guiding a more cautious stimulation protocol.

IVF and Assisted Reproduction Planning

Before any IVF or IUI cycle, clinicians need to know how the ovaries are likely to respond to gonadotrophin stimulation. AMH is the single best predictor of the number of eggs likely to be retrieved. FSH provides a cross-check. Together, they determine starting doses of stimulation medications, flag patients who may be poor responders or hyper-responders, and inform whether a cycle is likely to proceed or be cancelled.

Post-Cancer Fertility Assessment

Women who have received chemotherapy or pelvic radiation may experience significant loss of ovarian reserve. Serial AMH measurements allow clinicians to assess the impact of treatment, monitor recovery over time, and advise on the remaining fertility window and options for fertility preservation or assisted conception.

Monitoring After Ovarian Surgery

Surgical procedures on the ovaries, including cystectomy for endometriomas and surgery for ovarian torsion, can result in loss of ovarian tissue and a measurable drop in AMH. Post-operative AMH testing quantifies the impact of the surgery and helps guide decisions about future fertility treatment timelines. It is particularly relevant for women who require repeated ovarian surgeries, where the cumulative effect on the egg pool can be significant.

Who Should Get the AMH + FSH Test

• Women aged 30 and above planning a first or subsequent pregnancy who want a baseline fertility assessment.
• Those who have been trying to conceive for six months or more without success, particularly women aged 35 and above.
• Women preparing for IVF, IUI, or other forms of assisted reproduction.
• Patients with diagnosed or suspected PCOS, endometriosis, or premature ovarian insufficiency.
• Women experiencing irregular or absent periods, particularly under the age of 40.
• Those who have undergone chemotherapy, radiation therapy, or ovarian surgery.
• Women considering egg freezing for fertility preservation.
• Anyone seeking a proactive understanding of their reproductive timeline.

How to Prepare for Sample Collection

Fasting and timing

• Fasting is not strictly required for this test.
• Avoid strenuous exercise, alcohol, and heavy meals for 24 hours before collection.
• FSH is ideally collected on Day 2 or Day 3 of the menstrual cycle (Day 1 = first day of bleeding). Book your slot accordingly.
• AMH can be collected on any day of the cycle with no timing restriction.

Collection details

• Sample type: blood (serum).
• A certified MAX@Home phlebotomist visits your home at your scheduled time.
• All equipment is sterile and single-use.
• Report turnaround: typically 24 to 48 hours from sample receipt at the accredited partner lab.

What to tell your phlebotomist

• Mention if you are on hormonal contraception, as this suppresses AMH and FSH and may affect interpretability.
• Note the day of your menstrual cycle at the time of collection so the laboratory can flag whether the FSH timing is optimal.
• Inform the team of any recent acute illnesses or significant weight changes, which can transiently affect hormone levels.

Understanding Your AMH and FSH Results

AMH reference ranges (approximate)

• Greater than 3.5 ng/mL: High — often seen in PCOS; indicates a large follicle pool; may signal hyper-response risk during IVF stimulation.
• 1.0 to 3.5 ng/mL: Normal reproductive-age range — adequate ovarian reserve for the patient's age group.
• 0.5 to 1.0 ng/mL: Low-normal — fertility counselling is appropriate; natural conception may still be possible.
• Below 0.5 ng/mL: Significantly diminished reserve — specialist evaluation and fertility planning strongly advised.
• Undetectable: Consistent with premature ovarian insufficiency or natural menopause.

FSH reference ranges on Day 2/3 (approximate)

• Below 10 mIU/mL: Normal — adequate pituitary-ovarian communication.
• 10 to 15 mIU/mL: Borderline elevated — monitoring and repeat testing advised.
• Above 15 mIU/mL: Elevated — suggests diminished ovarian reserve.
• Above 25 mIU/mL: Significantly elevated — associated with perimenopause or ovarian failure.

Reading the two markers together

Low AMH with elevated FSH provides strong convergent evidence of diminished reserve. High AMH with low FSH and irregular cycles is a typical PCOS pattern. Discordant results, where the two markers point in different directions, require clinical interpretation by a gynaecologist or reproductive endocrinologist who will contextualise them within your full medical history and examination findings.

Next steps after results

A normal AMH and FSH result in a woman with no fertility concerns provides reassurance, though it does not guarantee future fertility or predict the chance of conception in any given cycle. An abnormal result is the beginning of a clinical conversation, not a verdict. In most cases the next steps include a consultation with a gynaecologist or reproductive endocrinologist, a pelvic ultrasound for antral follicle count, and where relevant, additional hormonal investigations to build a complete fertility profile before any treatment plan is established.

How to Book Your AMH + FSH Test with MAX@Home

1. Open the MAX@Home website or app and search for the AMH + FSH combination test.
2. Select your preferred date. If timing your FSH to Day 2 or 3, plan around your next cycle.
3. Confirm your address and any preparation instructions with the booking team.
4. A certified phlebotomist arrives at your home at the scheduled time with sterile equipment.
5. The sample is collected, labelled, and transported to the accredited partner laboratory.
6. Your digitally authenticated report is sent to your registered contact within 24 to 48 hours.

Why Choose MAX@Home for This Test

• Home collection gives you the flexibility to book on exactly the right cycle day for FSH without taking time off work or travelling to a clinic.
• All phlebotomists are trained and certified professionals using sterile, single-use equipment on every visit.
• Samples are transported under controlled conditions to accredited partner laboratories that meet NABL standards.
• Digitally authenticated reports are delivered securely to your registered device for easy sharing with your specialist.
• For patients managing fertility treatment cycles, the ability to book home collection on short notice is particularly valuable.
• The convenience of home testing removes practical barriers at what is often an emotionally significant time.